eligibility_summary
Eligible: ≥18, KPS ≥70, life ≥16 wk, CMV+ relapsed/refractory int/high-grade CD19+ B-cell NHL not eligible for/refusing/after autoHCT, no contraindications to apheresis/lymphodepletion, adequate organ function, LVEF ≥45%, O2 >92%. Exclude: recent growth factors/platelets/steroids, active autoimmune on IS, other therapy, arrhythmia or CNS immune disease, allergy/bleeding disorder, stroke/ICH <6 mo, infection, HIV/hepatitis, pregnancy/breastfeeding, uncontrolled illness/noncompliance, alloHCT if recovered, no GVHD.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05801913: Phase I, single-arm trial in relapsed/refractory intermediate/high-grade B‑cell NHL testing a combination of cellular gene therapy and a viral vector vaccine. Interventions: (1) Autologous CMV-specific CD19‑CAR T cells (genetically modified T lymphocytes expressing an anti‑CD19 chimeric antigen receptor) given IV after standard lymphodepletion. Mechanism: CAR-mediated recognition and killing of CD19+ malignant B cells. (2) CMV‑MVA Triplex (replication‑defective modified vaccinia Ankara vaccine encoding multiple CMV antigens) given IM at days 28 and 56. Mechanism: engages the native CMV specificity of the engineered T cells to drive TCR-mediated boosting, in vivo expansion, and persistence of CAR T cells. Targets: CD19 on B cells, CMV antigens to activate/expand CAR T cells, downstream T‑cell cytotoxic pathways.